Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?
- 30 June 2008
- Vol. 71 (6) , 1001-1006
- https://doi.org/10.1016/j.urology.2007.12.070
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The 'flare' phenomenon: should we be concerned?BJU International, 2005
- Estimated impact of the Prostate Cancer Prevention Trial on population mortalityCancer, 2005
- Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH AnaloguesEuropean Urology, 2004
- American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate CancerJournal of Clinical Oncology, 2004
- Gonadotropin-releasing-hormone-receptor antagonistsThe Lancet, 2001
- THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCERJournal of Urology, 2001
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)New England Journal of Medicine, 1989
- DISEASE FLARE INDUCED BY D-Trp6-LHRH ANALOGUE IN PATIENTS WITH METASTATIC PROSTATIC CANCERThe Lancet, 1984